Iron supplementation to treat anemia in patients with chronic kidney disease

Nature Reviews Nephrology

Volumn 6, Issue 12, 2010, Pages 699-710

  Besarab, Anatole ^a   Coyne, Daniel W ^b  

^a HENRY FORD HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; ERYTHROPOIETIN; HEPCIDIN; IRON;

CHRONIC KIDNEY FAILURE; HUMAN; IRON DEFICIENCY ANEMIA; METABOLISM; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA, IRON-DEFICIENCY; ANTIMICROBIAL CATIONIC PEPTIDES; ERYTHROPOIETIN; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 79955024469     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.139     Document Type: Article

References (90)

1. nd edn (Blackwell Scientific Publishing, 1979).
2. Sakiewicz, P & Paganini, E. The use of iron in patients on chronic dialysis: mistake and misconceptions. J. Nephrol. 11, 5-15 (1998).
3. Rabiner, S. F. Uremic bleeding. Prog. Hemost. Thromb. 1, 233-250 (1972).
4. Powell, N. & McNair, A. Gastrointestinal evaluation of anaemic patients without evidence of iron deficiency. Eur. J. Gastroenterol. Hepatol. 20, 1094-1100 (2008).
5. Gregory, C. G. & Eaves, A. C. Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biological properties. Blood 51, 527-537 (1978).
6. Jelkmann, W. & Hellwig-Burgel, T. Biology of erythropoietin. Adv. Exp. Med. Biol. 502, 169-187 (2001).
7. Besarab, A. & Yee, J. in Principles and Practice of Dialysis (ed. Henrich, W. L.) 499-523 (Lippincott, Williams and Wilkens, Baltimore, 2009).
8. Besarab, A. et al. The effects of normal versus anemic hematocrit on hemodialysis patients with cardiac disease. N. Engl. J. Med. 339, 584-590 (1998).
9. Fishbane, S. & Besarab, A. Mechanisms of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin. J. Am. Soc. Nephrol. 2, 1274-1282 (2007)
10. Besarab, A., Kaiser, J. W. & Frinak, S. A study of parenteral iron regimens in hemodialysis patients. Am. J. Kidney Dis. 34, 21-28 (1999).
11. Besarab, A. et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol. 11, 530-538 (2000).
12. Wish, J. B. Past, present, and future of chronic kidney disease anemia management in the United States. Adv. Chronic Kidney Dis. 16, 101-108 (2009).
13. Eschbach, J. W., Cook, J. D. & Finch, C. A. Iron absorption in chronic renal disease. Clin. Sci. 38, 191-201 (1970).
14. Eschbach, J. W., Cook, J. D., Scribner, B. H. & Finch, C. A. Iron balance in hemodialysis patients. Ann. Int. Med. 87, 710-713 (1977).
15. Magana, L., Dhar, S. K., Smith, E. C. & Martinez, C. Iron absorption and utilization in maintenance hemodialysis patients: oral and intravenous routes. Mt Sinai J. Med. 51, 180-183 (1984).
16. Hershko, C. & Skikne, B. Pathogenesis and management of iron deficiency anemia: emerging role of celiac disease, Helicobacter pylori, and autoimmune gastritis. Semin. Hematol. 46, 339-350 (2009).
17. Sugimoto, M., Sakai, K., Kita, M., Imanishi, J. & Yamaoka, Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int. 75, 96-103 (2009).
18. Al-Mueilo, S. H. Gastroduodenal lesions and Helicobacter pylori infection in hemodialysis patients. Saudi Med. J. 25, 1010-1014 (2004).
19. Waterlot, Y. et al. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: the critical role of iron overload. Br. Med. J. (Clin. Res. Ed.) 291, 501-504 (1985).
20. Seifert, A., von Herrath, D. & Schaefer, K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q. J. Med. 65, 1015-1024 (1987).
21. Kalantar-Zadeh, K., Don, B. R., Rodriguez, R. A. & Humphreys, M. H. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am. J. Kidney Dis. 37, 564-572 (2001).
22. Kalantar-Zadeh, K., Rodriguez, R. A. & Humphreys, M. H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol. Dial. Transplant. 19, 141-149 (2004).
23. Weiss, G. et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 64, 572-578 (2003).
24. Feldman, H. I. et al. Iron administration and clinical outcomes in hemodialysis patients. J. Am. Soc. Nephrol. 13, 734-744 (2002).
25. Feldman, H. I. et al. Administration of parenteral iron and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 15, 1623-1632 (2004).
26. Nemeth, E. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090-2093 (2004).
27. Tanno, T., Noel, P & Miller, J. L. Growth differentiation factor 15 in erythroid health and disease. Curr. Opin. Hematol. 17, 184-190 (2010).
28. Chasis, J. A. & Mohandas, N. Erythroblastic islands: niches for erythropoiesis. Blood 112, 470-478 (2008).
29. Babitt, J. L. & Lin, H. Y. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am. J. Kidney Dis. 55, 726-741 (2010).
30. Ganz, T., Olbina, G., Girelli, D., Nemeth, E. & Westerman, M. Immunoassay for human serum hepcidin. Blood 112, 4292-4297 (2008).
31. Nemeth, E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv. Hematol. 2010, 750-643 (2010).
32. Fernandez-Rodrfguez, A. M. et al. Diagnosis of iron deficiency in chronic renal failure. Am. J. Kidney Dis. 34, 508-513 (1999).
33. Kalantar-Zadeh, K. et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am. J. Kidney Dis. 26, 292-299 (1995).
34. Singh, A. K., Coyne, D. W., Shapiro, W., Rizkala, A. R. DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 71, 1163-1171 (2007).
35. Stancu, S. et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Clin. J. Am. Soc. Nephrol. 55, 639-647 (2010).
36. Stancu, S., Barsan, L., Stanciu, A. & Mircescu, G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease Clin. J. Am. Soc. Nephrol. 5, 409-416 (2010).
37. Bross, R. et al. Association of serum total iron- binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am. J. Nephrol. 29, 571-581 (2009).
38. Kalantar-Zadeh, K., McAllister, C. J., Lehn, R. S., Liu, E. & Kopple, J. D. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am. J. Kidney Dis. 43, 671-684 (2004).
39. Vaghefi, N. et al. Effect of stabilising amino acids on the digestive absorption of heme and non- heme iron. Reprod. Nutr. Dev. 38, 559-566 (1998).
40. Tonini, M., D’Angelo, L., Carminati, G. M. & De Bernardi, M. Intestinal absorption of iron. I. Interference of amino acids and polypeptides [Italian]. Boll. Chim. Farm. 118, 49-52 (1979).
41. Wingard, R. L., Parker, R. A., Ismail, N. & Hakim, R. M. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am. J. Kidney Dis. 25, 433-439 (1995).
42. Markowitz, G. S., Kahn, G. A., Feingold, R. E., Coco, M. & Lynn, R. I. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin. Nephrol. 48, 34-40 (1997).
43. Nissenson, A. R. et al. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am. J. Kidney Dis. 42, 325-330 (2003).
44. Ofalabi, O., Velarde, C. & Besarab, A. Efficacy and tolerance of heme iron peptide (HIP) compared to iron fumurate (IF) in CKD patients [abstract]. J. Am. Soc. Nephrol. 14, 793A (2003).
45. Sepandj, F., Jindal, K., West, M. & Hirsch, D. Economic appraisal of maintenance parenteral iron administration in treatment of the anaemia in chronic haemodialysis patients. Nephrol. Dial. Transplant. 11, 319-322 (1996).
46. Yee, J. & Besarab, A. Iron sucrose: the oldest therapy becomes new. Am. J. Kidney Dis. 40, 1111-1121 (2002).
47. Bolanos, L. et al. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am. J. Nephrol. 22, 67-72 (1992).
48. Bregman, H. & Gelfand, M. C. Iron overload in patients on maintenance hemodialysis. Int. J. Artif. Organs 4, 56-57 (1981).
49. Ali, M. et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1, 652-655 (1982).
50. Gokal, R. et al. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. Q. J. Med. 48, 369-391 (1979).
51. Winchester, J. F. Management of iron overload in dialysis patients. Semin. Nephrol. 6, 22-26 (1986).
52. Barany, P, Eriksson, L. C., Hultcrantz, R., Pettersson, E. & Bergstrom, J. Serum ferritin and tissue iron in anemic dialysis patients. Miner. Electrolyte Metab. 23, 273-276 (1997).
53. Rodgers, G. M. et al. High-molecular weight iron dextran: a wolf in sheep’s clothing? J. Am. Soc. Nephrol. 19, 833-840 (2008).
54. Raimundo, M., Abreu, F. & Da Costa, G. Parenteral iron safety in haemodialysis patients. Port. J. Nephrol. Hyperten. 23, 153-159 (2009).
55. Nissenson, A. R., Lindsay, R. M., Swan, S., Seligman, P. & Strobos, J. Sodium ferric gluconate complex in surcrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am. J. Kidney Dis. 33, 471-482 (1999).
56. Bailie, G. R., Johnson, C. A. & Mason, N. A. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am. J. Kidney Dis. 35, 1-12 (2000).
57. Chandler, G., Harchawal, K. & Macdougall, I. C. Intravenous iron sucrose: establishing a safe dose. Am. J. Kidney Dis. 38, 988-991 (2001).
58. Spinowitz, B. S. et al. Ferumoxytol for treating iron deficiency anemia in CKD. J. Am. Soc. Nephrol. 19, 1599-1605 (2008).
59. Singh, A. et al. Safety of ferumoxytol in patients with anemia and, CKD. Am. J. Kidney Dis. 52, 907-915 (2008).
60. Macdougall, I. C. Evolution of IV iron compounds over the last century. J. Ren. Care 35 (Suppl. 2), 8-13 (2009).
61. Himmelfarb, J., Stenvinkel, P, Ikizler, T. A. & Hakim, R. M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 62, 1524-1538 (2002).
62. Zager, R. A., Johnson, A. C., Hanson, S. Y. & Wasse, H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am. J. Kidney Dis. 40, 90-103 (2002).
63. Drueke, T. et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106, 2212-2217 (2002).
64. Himmelfarb, J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin. Dial. 22, 636-643 (2009).
65. Bishu, K. & Agarwal, R. Acute injury with intravenous iron and concerns regarding long- term safety. J. Am. Soc. Nephrol. 1 (Suppl. 1), S19-S23 (2006).
66. Causse, E. et al. Aminothiols and allantoin in chronic dialysis patients: effects of hemodialysis sessions. Clin. Nephrol. 73, 51-57 (2010).
67. Shah, S. V. & Rajapurkar, M. M. The role of labile iron in kidney disease and treatment with chelation. Hemoglobin 33, 378-385 (2009).
68. Kalantar-Zadeh, K., Regidor, D. L., McAllister, C. J., Michael, B. & Warnock, D. G. Time-dependent associations between iron and mortality in hemodialysis patients. J. Am. Soc. Nephrol. 16, 3070-3080 (2005).
69. Kovesdy, C. S., Estrada, W., Abmahdzadeh, S. & Kalantar-Zadeh, K. Association of iron markers of iron stores with outcomes in patients with non-dialysis-dependent chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 435-541 (2009).
70. Pollack, V. E., Lorxh, J. A., Schukla, R. & Satwah, S. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alpha and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol. 10, 6 (2009).
71. Agarwal, R., Rizkala, A. R., Kaskas, M. O. & Trout, J. R. Iron sucrose causes greater proteinuria than ferric gluconate in non- dialysis chronic kidney disease. Kidney Int. 72, 638-642 (2007).
72. Coyne, D. W. et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J. Am. Soc. Nephrol. 18, 975-984 (2007).
73. Anker, S. D. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436-2448 (2009).
74. Agarwal, R. A clinical trial of oral versus IV iron in patients with chronic kidney disease. ClinicalTrial. gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00830037?term=NCT00830037& rank=1 (2010).
75. Mircescu, G. Intravenous iron in patients with severe chronic heart failure and chronic kidney disease. ClinicalTrial.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00384657 ?term=NCT00384657&rank=1 (2010).
76. Dahl, N. V., Henry, D. H. & Coyne, D. W. Thrombosis with erythropoietic stimulating agents—does iron-deficient erythropoiesis play a role? Semin. Dial. 21, 210-211 (2008).
77. Streja, E. et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am. J. Kidney Dis. 52, 727-736 (2008).
78. Besarab, A., Rayamajhi, S., Al-Sharif, H., Frinak, S. & Yee, J. Iron repletion decreases platelet counts (PLT) in non-dialysis CKD patients [abstract 50]. Am. J. Kidney Dis. 55 (Suppl.), B54 (2010).
79. Vaziri, N. D. Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency. Am. J. Kidney Dis. 53, 733-736 (2009).
80. Gotloib, L., Silverberg, D., Fudin, R. & Shostak, A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J. Nephrol. 19, 161-167 (2006).
81. Macdougall, I. C. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr. Med. Res. Opin. 26, 473-482 (2010).
82. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).
83. Soman, S., Zasuwa, G. & Yee, J. Automation, decision support, and expert systems in nephrology. Adv. Chronic Kidney Dis. 15, 42-55 (2008).
84. Covic, A. & Mircescu, G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol. Dial. Transplant. 25, 2722-2730 (2010).
85. Provenzano, R. et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4, 386-393 (2009).
86. Gupta, A. et al. Dialysate iron therapy: infusion of soluble ferric pyprophosphate via the dialysate during hemodialysis. Kidney Int. 55, 1891-1898 (1999).
87. Gastaldello, K. et al. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol. Dial. Transplant. 10 (Suppl. 6), 44-67 (1995).
88. Attallah, N., Osman-Malik, Y., Frinak, S. & Besarab, A. Effect of intravenous ascorbic acid in hemodialysis patients with erythropoietin-hyporesponsive anemia and hyperferritinemia. Am. J. Kidney Dis. 47, 644-654 (2006).
89. Goch, J., Birgegard, G., Danielson, B. G. & Wikstrom, B. Treatment of erythropoietin- resistant anaemia with desferrioxamine in patients on haemofiltration. Eur. J. Haematol. 55, 73-77 (1995).
90. Sargent, J. A. & Acchiardo, S. R. Iron requirements in hemodialysis. Blood Purif. 2, 12-23 (2004).